US 12,226,466 B2
Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
Andrea Mahr, Tuebingen (DE); Toni Weinschenk, Aichwald (DE); Helen Hoerzer, Tuebingen (DE); Oliver Schoor, Tuebingen (DE); Jens Fritsche, Dusslingen (DE); and Harpreet Singh, Munich (DE)
Assigned to Immatics Biotechnologies GmbH, Tübingen (DE)
Filed by Immatics Biotechnologies GmbH, Tuebingen (DE)
Filed on May 28, 2021, as Appl. No. 17/333,902.
Application 17/333,902 is a continuation of application No. 16/864,558, filed on May 1, 2020, granted, now 11,065,314.
Application 16/864,558 is a continuation of application No. 16/752,156, filed on Jan. 24, 2020, granted, now 10,675,338, issued on Jun. 9, 2020.
Application 16/752,156 is a continuation of application No. 16/582,096, filed on Sep. 25, 2019, granted, now 10,596,243, issued on Mar. 24, 2020.
Application 16/582,096 is a continuation of application No. 16/456,815, filed on Jun. 28, 2019, granted, now 10,485,859, issued on Nov. 26, 2019.
Application 16/456,815 is a continuation of application No. 16/210,357, filed on Dec. 5, 2018, granted, now 10,376,569, issued on Aug. 13, 2019.
Application 16/210,357 is a continuation of application No. 16/024,164, filed on Jun. 29, 2018, granted, now 10,166,278, issued on Jan. 1, 2019.
Application 16/024,164 is a continuation of application No. 16/065,681, granted, now 10,213,499, issued on Feb. 26, 2019, previously published as PCT/EP2016/079059, filed on Nov. 29, 2016.
Claims priority of provisional application 62/270,968, filed on Dec. 22, 2015.
Claims priority of application No. 1522667 (GB), filed on Dec. 22, 2015.
Prior Publication US 2021/0290743 A1, Sep. 23, 2021
Int. Cl. A61K 38/00 (2006.01); A61K 35/17 (2015.01); A61K 38/08 (2019.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C07K 7/06 (2006.01); C07K 14/47 (2006.01); C07K 14/72 (2006.01); C07K 14/725 (2006.01); C07K 16/00 (2006.01); C07K 16/28 (2006.01); C12N 15/115 (2010.01); A61K 39/39 (2006.01); C07K 7/00 (2006.01)
CPC A61K 39/0011 (2013.01) [A61K 35/17 (2013.01); A61K 38/08 (2013.01); A61K 38/1709 (2013.01); A61K 39/4611 (2023.05); A61K 39/4644 (2023.05); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07K 7/06 (2013.01); C07K 14/4748 (2013.01); C07K 14/7051 (2013.01); C07K 14/721 (2013.01); C07K 16/00 (2013.01); C07K 16/2833 (2013.01); C12N 15/115 (2013.01); A61K 38/00 (2013.01); A61K 39/39 (2013.01); A61K 2039/812 (2018.08); C07K 7/00 (2013.01); C07K 2317/41 (2013.01); C12N 2310/16 (2013.01)] 17 Claims
 
1. An isolated peptide consisting of the amino acid sequence FSFPVSVGV (SEQ ID NO: 20) in the form of a pharmaceutically acceptable salt, wherein said peptide is produced by solid phase peptide synthesis or produced by a yeast cell or bacterial cell expression system.